| Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer LB Saltz, JV Cox, C Blanke, LS Rosen, L Fehrenbacher, MJ Moore, ... New England Journal of Medicine 343 (13), 905-914, 2000 | 3962 | 2000 |
| Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line … MER O’Brien, N Wigler, M Inbar, R Rosso, E Grischke, A Santoro, ... Annals of oncology 15 (3), 440-449, 2004 | 1972 | 2004 |
| Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial BH Burmeister, BM Smithers, V Gebski, L Fitzgerald, RJ Simes, P Devitt, ... The lancet oncology 6 (9), 659-668, 2005 | 1124 | 2005 |
| Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation … SY Ngan, B Burmeister, RJ Fisher, M Solomon, D Goldstein, D Joseph, ... Journal of clinical oncology 30 (31), 3827-3833, 2012 | 1059 | 2012 |
| Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III … NC Tebbutt, K Wilson, VJ Gebski, MM Cummins, D Zannino, ... Journal of clinical oncology 28 (19), 3191-3198, 2010 | 517 | 2010 |
| Basis for effective combination cancer chemotherapy with antimetabolites GJ Peters, CL Van der Wilt, CJA Van Moorsel, JR Kroep, AM Bergman, ... Pharmacology & therapeutics 87 (2-3), 227-253, 2000 | 397 | 2000 |
| High-dose methotrexate: a critical reappraisal. SP Ackland, RL Schilsky Journal of Clinical Oncology 5 (12), 2017-2031, 1987 | 329 | 1987 |
| Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer JF Bishop, J Dewar, GC Toner, J Smith, MHN Tattersall, IN Olver, ... Journal of Clinical Oncology 17 (8), 2355-2355, 1999 | 267 | 1999 |
| Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines DC Talbot, V Moiseyenko, S Van Belle, SM O'reilly, E Alba Conejo, ... British journal of cancer 86 (9), 1367-1372, 2002 | 250 | 2002 |
| Nutrition support improves patient outcomes, treatment tolerance and admission characteristics in oesophageal cancer C Odelli, D Burgess, L Bateman, A Hughes, S Ackland, J Gillies, ... Clinical oncology 17 (8), 639-645, 2005 | 230 | 2005 |
| Phase II trial of pemetrexed disodium (ALIMTA®, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer SJ Clarke, R Abratt, L Goedhals, MJ Boyer, MJ Millward, SP Ackland Annals of oncology 13 (5), 737-741, 2002 | 210 | 2002 |
| Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer MR Stockler, VJ Harvey, PA Francis, MJ Byrne, SP Ackland, B Fitzharris, ... Journal of clinical oncology 29 (34), 4498-4504, 2011 | 190 | 2011 |
| Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer A Sobrero, S Ackland, S Clarke, R Perez-Carrión, S Chiara, J Gapski, ... Oncology 77 (2), 113-119, 2008 | 168 | 2008 |
| Comparison of 5-fluoro-2′-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer JAM Van Laar, YM Rustum, SP Ackland, CJ Van Groeningen, GJ Peters European Journal of Cancer 34 (3), 296-306, 1998 | 158 | 1998 |
| Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines A McCluskey, SP Ackland, MC Bowyer, ML Baldwin, J Garner, ... Bioorganic chemistry 31 (1), 68-79, 2003 | 153 | 2003 |
| Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial International Breast Cancer Study Group (IBCSG) Journal of the National Cancer Institute 94 (14), 1054-1065, 2002 | 150 | 2002 |
| Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international … TJ Price, D Zannino, K Wilson, RJ Simes, J Cassidy, GA Van Hazel, ... Annals of oncology 23 (6), 1531-1536, 2012 | 147 | 2012 |
| The physical and psycho‐social experiences of patients attending an outpatient medical oncology department: a cross‐sectional study Newell, Girgis, Ackland European journal of cancer care 8 (2), 73-82, 1999 | 139 | 1999 |
| Acute adverse events and postoperative complications in a randomized trial of preoperative short-course radiotherapy versus long-course chemoradiotherapy for T3 adenocarcinoma … N Ansari, MJ Solomon, RJ Fisher, J Mackay, B Burmeister, S Ackland, ... Annals of surgery 265 (5), 882-888, 2017 | 136 | 2017 |
| Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. HP Gurney, S Ackland, V Gebski, G Farrell Journal of clinical oncology 16 (7), 2299-2304, 1998 | 136 | 1998 |
